Avila J et al. Frequency of presentation and outcomes of stage IV breast cancer over the past decade: A population-based study. San Antonio Breast Cancer Symposium 2023;Abstract PO4-06-02.
Bardia A et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol 2024;[Online ahead of print]. Abstract
Bardia A et al. ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC). ESMO 2022;Abstract 275TiP.
Brastianos PK et al. Pembrolizumab in brain metastases of diverse histologies: Phase 2 trial results. Nat Med 2023;29(7):1728-37. Abstract
Chen N et al. The evolving therapeutic landscape of antibody-drug conjugates in breast cancer. Expert Rev Anticancer Ther 2022;22(12):1325-31. Abstract
Cortes J et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022;387(3):217-26. Abstract
Foldi J, Geyer CE Jr. Precision medicine for metastatic TNBC: The FUTURE is now. Cell Res 2023;33(7):491-2. Abstract
Howard FM et al. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2022;195(1):1-15. Abstract
Howard FM et al. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs 2022;31(6):531-48. Abstract
Huppert LA et al. Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol 2022;14:17588359221086916. Abstract
Jacob SL et al. Role of immunotherapy in breast cancer. JCO Oncol Pract 2023;19(4):167-79. Abstract
Kalinsky K et al. Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC). ESMO 2023;Abstract 393P.
Kim AE et al. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance. Neuro Oncol 2023;[Online ahead of print]. Abstract
Leone JP et al. Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool. Eur J Cancer 2023;189:112930. Abstract
Morganti S et al. Adjuvant olaparib for germline BRCA carriers with HER2-negative early breast cancer: Evidence and controversies. Oncologist 2023;28(7):565-74. Abstract
Morganti S, Tolaney SM. Role of immunotherapy in early- and late-stage triple-negative breast cancer. Hematol Oncol Clin North Am 2023;37(1):133-50. Abstract
Notini G et al. Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice. Front Oncol 2024;14:1374547. Abstract
Rugo HS et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 2023;19(8):539-46. Abstract
Schlam I et al. How I treat HER2-low advanced breast cancer. Breast 2023;67:116-23. Abstract
Schlam I et al. Managing adverse events of sacituzumab govitecan. Expert Opin Biol Ther 2023;23(11):1103-11. Abstract
Schlam I et al. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. Crit Rev Oncol Hematol 2023;190:104090. Abstract
Schmid P et al. Datopotamab deruxtecan (DATO-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC). ESMO 2023;Abstract 379MO.
Schreiber AR et al. The emergence of targeted therapy for HER2-low triple-negative breast cancer: A review of fam-trastuzumab deruxtecan. Expert Rev Anticancer Ther 2023;23(10):1061-9. Abstract
Senkus E et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer 2023;153(4):803-14. Abstract
Shaikh SS, Emens LA. Current and emerging biologic therapies for triple negative breast cancer. Expert Opin Biol Ther 2022;22(5):591-602. Abstract
Tarantino P et al. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023;20(8):558-76. Abstract
Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: The five “S” rules. JCO Oncol Pract 2023;19(8):526-7. Abstract
Teli et al. Recent advances in triple-negative breast cancer. San Antonio Breast Cancer Symposium 2023;Abstract PL-02.